title: Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis.
abstract: Altered peptide ligands that alter immune responses are a promising approach to the immunotherapy of multiple sclerosis. Cyclic peptides are of interest because the limited stability of linear peptides restricts their use in vivo. We designed and synthesized a cyclic double mutant peptide from MBP(87-99)-[cyclo(87-99)[A(91),A(96)]MBP(87-99)]. Immunization of mice, in CFA reduced Th1 responses. However, when conjugated to reduced mannan, a significant further reduction of Th1 responses and moderate Th2 responses were induced.
authors.affiliation: Burnet Institute, Immunology and Vaccine Laboratory, Heidelberg, VIC, Australia.
authors.forename: Maria
authors.initials: M
authors.lastname: Katsara
authors.forename: George
authors.initials: G
authors.lastname: Deraos
authors.forename: Theodore
authors.initials: T
authors.lastname: Tselios
authors.forename: Minos-Timotheos
authors.initials: MT
authors.lastname: Matsoukas
authors.forename: Irene
authors.initials: I
authors.lastname: Friligou
authors.forename: John
authors.initials: J
authors.lastname: Matsoukas
authors.forename: Vasso
authors.initials: V
authors.lastname: Apostolopoulos
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D007167:Immunotherapy; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008351:Mannans / Q000737:chemistry*; D051379:Mice; D009103:Multiple Sclerosis / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D009154:Mutation / Q000235:genetics; D004676:Myelin Basic Protein / Q000138:chemical synthesis* / Q000737:chemistry / Q000235:genetics; D010446:Peptide Fragments / Q000138:chemical synthesis* / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000138:chemical synthesis* / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D008351:Mannans; D004676:Myelin Basic Protein; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D015847:Interleukin-4; D007371:Interferon-gamma